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Reduced (FeII) Rhodopseudomonas palustris cytochrome c* (Cyt c*)
is more stable toward unfolding ([GuHCl]1/2 5 2.9(1) M) than the
oxidized (FeIII) protein ([GuHCl]1/2 5 1.9(1) M). The difference in
folding free energies (DDGf° 5 70 meV) is less than half of the
difference in reduction potentials of the folded protein (100 mV vs.
NHE) and a free heme in aqueous solution (’2150 mV). The
spectroscopic features of unfolded FeII–Cyt c* indicate a low-spin
heme that is axially coordinated to methionine sulfur (Met-15 or
Met-25). Time-resolved absorption measurements after CO photo-
dissociation from unfolded FeII(CO)–Cyt c* confirm that methionine
can bind to the ferroheme on the microsecond time scale [kobs 5
5(2) 3 104 s21]. Protein folding was initiated by photoreduction
(two-photon laser excitation of NADH) of unfolded FeIII–Cyt c*
([GuHCl] 5 2.02–2.54 M). Folding kinetics monitored by heme
absorption span a wide time range and are highly heterogeneous;
there are fast-folding (’103 s21), intermediate-folding (102–101
s21), and slow-folding (1021 s21) populations, with the last two
likely containing methionine-ligated (Met-15 or Met-25) ferrohe-
mes. Kinetics after photoreduction of unfolded FeIII–Cyt c* in the
presence of CO are attributable to CO binding [1.4(6) 3 103 s21] and
FeII(CO)–Cyt c* folding [2.8(9) s21] processes; stopped-flow trig-
gered folding of FeIII–Cyt c* (which does not contain a protein-
derived sixth ligand) is adequately described by a single kinetics
phase with an estimated folding time constant of ’4 ms [DGf° 5
233(3) kJ mol21] at zero denaturant.
Energy-landscape descriptions of protein folding emphasizethe roles of free energy and energy-surface ruggedness as key
determinants of folding dynamics (1–3). The many correlations
of folding times with free energy support this point of view, but
it is difficult to reconcile the model with the seemingly simple
kinetics that often are observed. Analyses of experimental data
point to a relationship between the folding kinetics and the
topology of the native protein structure (4–8). Proteins that, on
average, have a large number of long-range contacts in the
folded state tend to fold more slowly than those with a prepon-
derance of short-range contacts. The questions remain: is it the
depth and roughness of the funnel, the topology of the folded
state, or some combination of the two that determines the
folding mechanism?
Short-range contacts outnumber long-range interactions in
helical bundles; if topology is the key, then these proteins should
fold rapidly (4, 5). Highly helical ferrocytochrome b562 (FeII–Cyt
b562) (9, 10), acyl-CoA binding protein (ACBP) (11–14), the E
colicin binding immunity proteins Im7 and Im9 (15, 16), and the
N-terminal domain of phage l repressor (17) all fold on the
millisecond time scale. These observations appear to support the
notion that folded-state structural topology is of central impor-
tance in folding dynamics and that helical bundle structures are
inherently fast folding.
We have shown previously that FeII–Cyt b562 folding can be
triggered by electron transfer (ET), a method that takes advan-
tage of the greater stabilities of reduced heme proteins in native
states (9, 10, 18, 19). Although folded FeII–Cyt b562 was observed
within milliseconds after reduction of the unfolded oxidized
protein, no more than half of the reduced protein successfully
developed native structure (10). Rapid heme dissociation from
the polypeptide (kdiss ’2–7 3 103 s21) limited the yield of the
folding reaction. The heme-loss step selects fast-folding confor-
mations from the unfolded ensemble; if there are slow-folding
components, they cannot be detected. Under these circum-
stances, the observed kinetics reflect heme-dissociation dynam-
ics rather than folding.
Cytochrome c9 (Cyt c9) from the photosynthetic bacterium
Rhodopseudomonas palustris is a monomeric, soluble, 125-
residue, four-helix-bundle heme protein. Importantly, the por-
phyrin is bound to the polypeptide with two thioether links near
the C terminus (Cys-113 and Cys-116) (20–22). Although sharing
just 19% sequence identity and 40% similarity (23), Cyt c9 and
Cyt b562 have quite similar folds (1.6-Å rms deviation in a-carbon
position) (Fig. 1) (24, 25). Cyt b562 has a six-coordinate, low-
spin heme with Met-7 and His-102 axial ligands
[(H102N){PorN4FeIII}(M7S)1] and a reduction potential of 180 mV
vs. NHE (24, 26). Cyt c9 has a high-spin, five-coordinate heme,
axially ligated by His-117 [(H117N){PorN4FeIII}1] and a reduction
potential of 100 mV (27–32). In Cyt c9, the side-chain of Leu-12
fills the space occupied by a sixth ligand in Cyt b562 (Fig. 1 Inset)
(25); movement of this bulky group is necessary for ligand
binding.
The FeIII/II reduction potential is high enough to permit ET
triggering of FeII–Cyt c9 folding in the 2.0–2.9 M guanidine
hydrochloride (GuHCl) concentration range. FeII–Cyt c9 folding
is highly heterogeneous, spanning a time range from millisec-
onds to several seconds. Importantly, the folding kinetics of
FeIII–Cyt c9 and FeII(CO)–Cyt c9 are less complex, indicating
that nonnative ligand traps may be responsible for the complex-
ity of FeII–Cyt c9 folding.
Materials and Methods
GuHCl (Sigma, ultrapure grade), Tris(2,29-bipyridine)rutheni-
um(II) chloride ([Ru(bpy)3]Cl2, Strem), and NADH (Sigma)
were used as received.
Spectroscopic measurements were made as follows: absorp-
tion, Hewlett-Packard 8452 diode array spectrophotometer; CD,
Aviv 62ADS spectropolarimeter; and luminescence, Hitachi
F-4500 spectrofluorimeter (lex 5 290 nm; lobsd 5 300–500 nm).
Mass spectral analyses were done at the ProteinyPeptide Mi-
croanalytical Laboratory in the Beckman Institute at Caltech.
R. palustris strain 37 (ATCC 17007) Cyt c9 was isolated and
purified by using minor modifications of published procedures
(31, 33). Cyt c9 was chromatographed either on a CM Sepharose
column equilibrated with 5 mM sodium phosphate and 10 mM
NaCl (pH 7.0) in the presence of ferricyanide and eluted with the
charging buffer, or on a column of hydroxyapatite (type I,
Bio-Rad) equilibrated with 3 mM sodium phosphate and 15 mM
NaCl (pH 7.0) in the presence of mercaptoethanol and eluted
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with a linear gradient from 10 mM to 100 mM sodium phosphate
buffer (15 mM NaCl, pH 7.0). Proteins used in all experiments
had purity indices (A280 nmyA398 nm, oxidized) between 0.22 and
0.25 (literature value, 0.21) (33). Although only a single fraction
was isolated chromatographically, mass spectra revealed two
components in the protein sample. The mass of one component
matched that expected on the basis of the amino acid sequence
(13,748 daltons); the other had a mass 17 atomic mass units lower
than predicted. Protein concentrations were obtained from
UV-visible absorption measurements (FeIII–Cyt c9, «398 nm 5 85
mM21cm21; FeII–Cyt c9, «426 nm 5 99 mM21cm21) (34). GuHCl
concentrations were extracted from refractive index determina-
tions (Abbe-3L refractometer, Milton Roy, Rochester, NY) (35).
Denaturation curves for FeII–Cyt c9 were determined in the
presence of excess sodium dithionite. Transient absorption spec-
tra and kinetics were measured by using an apparatus described
previously (36). The excitation source was the third harmonic of
a Q-switched Nd:YAG laser (355 nm) for electron photoinjec-
tion from NADH, and a Nd:YAG pumped optical parametric
oscillator (480 nm) for injection from Ru(bpy)3
21 and for CO
photolysis experiments. A 16-bit, 20 MSys digital oscilloscope
(CompuScope 1602, Gage Applied) was used to record the
complete kinetics traces from 1023 to 101 s. Samples for kinetics
measurements were deoxygenated by repeated evacuationy
argon-fill cycles on a Schlenk line. Typical samples contained Cyt
c9 (100–200 mM), either Ru(bpy)3
21 (1.0–1.5 equivalents) or
NADH (2.0–2.5 equivalents), and GuHCl (1.8–3.5 M) in 100
mM sodium phosphate buffer (pH 7). The pH and index of
refraction were measured after laser experiments. Reduced
protein was stirred under 1 atm of CO for at least 30 min after
deoxygenation to prepare FeII(CO)–Cyt c9.
Measured kinetics traces were logarithmically compressed
(100 points per time decade), normalized [I(t) 2 I(t‘)yI(t0) 2
I(t‘)], and fit by using a non-negative linear least-squares min-
imization algorithm to project the folding kinetics onto a basis of
exponential decay functions with rate constants in the range 105
to 1022 s21 (10 rate constants per decade, spaced logarithmi-
cally).
The folding kinetics of FeIII–Cyt c9 were measured by using a
BioLogic SFM-4S stopped-flow mixer, coupled via optical fiber
to a monochromator fitted with a five-stage photomultiplier
tube. Probe light was provided by a 200-W HgyXe arc lamp. The
PMT output was recorded with the 16-bit digital oscilloscope.
Kinetics traces were measured at 372 nm (formation of folded
protein, D« 5 28 mM21 cm21) and 400 nm (disappearance of the
unfolded protein, D« 5 244 mM21 cm21) for a time period up
to 25 s, at a sampling rate of 2 or 5 kSys. In all refolding
experiments, unfolded FeIII–Cyt c9 (3.3 M GuHCl) was either
diluted 6- or 12-fold with a combination of Hepes buffer
([Hepes] 5 0.1 M, pH 7) and HepesyGuHCl ([Hepes] 5 0.1 M,
[GuHCl] 5 3.3 M, pH 7), giving final protein concentrations of
1.5 mM and varying GuHCl concentrations (0.6–1.80 M). Ki-
netics traces were fit to single exponential functions.
Results
Equilibrium Unfolding. GuHCl titration curves generated from
far-UV CD, Trp-72 fluorescence, and Soret absorbance spectra
show that reduced Cyt c9 is more stable toward unfolding
([GuHCl]1/2 5 2.9(1) M) than oxidized Cyt c9 ([GuHCl]1/2 5
1.9(1) M) (Fig. 2 Inset). The stability of folded Cyt c9, judged by
the folding free-energy change extrapolated to zero denaturant
(DGf°), is measurably lower than that of Cyt b562 [Fe(III):
DGf°(Cyt c9) 5 233(3) kJ mol21, DGf°(Cyt b562) 5 242(3) kJ
mol21; Fe(II): DGf°(Cyt c9) 5 240(4) kJ mol21, DGf°(Cyt b562)
’278 kJ mol21]. The difference in folding free energies between
FeIII– and FeII–Cyt c9 (DDGf° 5 7 kJ mol21 ’70 meV) is less than
half that predicted on the basis of the reduction potential of the
folded protein (100 mV vs. NHE) and the potential expected for
a heme in aqueous solution (2150 mV) (37). The titrations
suggest that the potential of the unfolded protein is ’0 V,
possibly because a second axial ligand binds to the heme when
the protein unfolds. Although the difference in folding free
energies is smaller than anticipated, it is large enough to permit
ET triggering of FeII–Cyt c9 folding between 2 and 2.9 M GuHCl.
Ligand Binding to Unfolded Cyt c*. Addition of GuHCl to solutions
of FeIII–Cyt c9 narrows the Soret absorption band (lmax 5 400
nm, « 5 133 mM21zcm21) (Fig. 2). The absorption profile is
analogous to that of the M80A mutant of cytochrome c (lmax 5
400 nm, « 5 164 mM21zcm21, pH 5 4.5) (38) and is consistent
Fig. 1. Comparison of heme environments. In Cyt b562 (gray), the heme iron
is axially ligated to His-102 and Met-7, whereas in Cyt c9 (black), the heme has
only one axial ligand (His-117) with the side chain of Leu-12 at the other axial
site. The nearest methionine residue (Met-15) in Cyt c9 is also shown. Backbone
atoms of four a-helices of Cyt c9 (PDB 1A7V) are superimposed on the corre-
sponding atoms in Cyt b562 (PDB 256B), with a calculated rms deviation of
1.6 Å.
Fig. 2. Absorption spectra of folded FeIII–Cyt c9 and FeII–Cyt c9 (bold lines),
and unfolded FeIII–Cyt c9 and FeII–Cyt c9 (dashed lines). (Inset) GuHCl titration
curves generated from CD, fluorescence, and Soret absorption data (xu is the
unfolded-protein fraction).







with the formation of a six-coordinate, high-spin heme (H117N)
{PorN4FeIII}(OH2)1. The absorption spectrum in alkaline solu-
tion (pH .10, [GuHCl] $ 3.5 M) is typical of a low-spin FeIII
heme (lmax 5 406 nm, « 5 100 mM21zcm21) (38); in this case,
it is possible that a lysine residue binds to form
(H117N){PorN4FeIII}(KN)1. Unlike cytochrome c, Cyt c9 has no
His residues (other than the native His-117 ligand) available to
bind to the FeIII heme in the unfolded protein.
GuHCl denaturation induces a blue shift in the Soret absorp-
tion of FeII–Cyt c9 (folded: lmax 5 426, 435 nm; unfolded: lmax
5 420 nm), and two sharp Q-bands then appear (lmax 5 524, 552
nm). These spectroscopic features are consistent with a six-
coordinate, low-spin heme (Fig. 2). The absence of strongly
shifted peaks in the 1H NMR spectrum of unfolded FeII–Cyt c9
also signals the presence of a diamagnetic heme. The absorption
spectrum of the unfolded FeII protein is independent of pH in
the range 4–10, although changes in Soret absorption at higher
pH levels are consistent with lysine binding (lmax 5 416, 520, 550
nm). Addition of N-acetyl-L-methionine to unfolded FeII–Cyt c9
causes little perturbation of the spectrum, suggesting methionine
sulfur coordination [(H117N){PorN4FeII}(MS), Met-15 andyor
Met-25] in unfolded FeII–Cyt c9. Methionine binding in unfolded
FeII–Cyt c9 would raise the reduction potential and could explain
the small difference between the folding free-energy changes in
FeII– and FeIII–Cyt c9.
Misligated Met residues must dissociate from the heme before
Cyt c9 can adopt its native folded structure. Indeed, the folding
dynamics of FeII–Cyt c9 could reflect the kinetics of ligand
substitutions. We have used two methods to examine the kinetics
of MS binding to FeII in unfolded Cyt c9. Laser-excited Ru(bpy)3
21
reduces unfolded FeIII–Cyt c9 ([GuHCl] 5 4.4 M) in less than a
microsecond. After the rapid [1.4(1) 3 106 s21] change in
absorbance corresponding to heme reduction, there is no sub-
stantial variation in the spectrum of the reduced protein until
charge recombination regenerates unfolded FeIII–Cyt c9. The
transient difference spectrum recorded 20 ms after the laser flash
reveals a mixture of high- and low-spin hemes, suggesting that a
nonnative sixth ligand rapidly binds to the heme in the unfolded
reduced protein. Ligand binding dynamics also were examined
after photodissociation of CO from unfolded FeII(CO)-Cyt c9
(4.5 M GuHCl, pH 7). The transient absorption difference
spectrum measured immediately after CO dissociation (t 5 100
ns) exhibits a broad feature in the Q-band region (530–570 nm)
corresponding to a five-coordinate heme (H117N) {PorN4FeII}.
Subsequent absorption changes arise from the formation of a
low-spin heme [kobs 5 5(2) 3 104 s21] before CO rebinding. Both
experiments indicate that MS can bind to the heme in unfolded
FeII–Cyt c9 on the microsecond time scale (39–42).
FeII-Cyt c* Folding. FeII–Cyt c9 folding was initiated by rapid
electron injection (’100 ms) into unfolded oxidized protein
([GuHCl] 5 2.02–2.54 M) after two-photon laser excitation of
NADH (43, 44). Under these conditions, heme reduction is
slower than binding of the nonnative sixth ligand. The progress
of the folding reaction was monitored by heme absorption in the
Soret and Q-band regions from 1024 to 1 s after excitation. The
observed kinetics are highly heterogeneous. A small fraction
(’20%) of the population forms a high-spin heme species in
about a millisecond. Complete formation of the fully folded
ensemble requires several seconds (Fig. 3). Rate constants for
FeII–Cyt c9 span a range from 103 to 1021 s21 revealing fast-
folding (7.0 3 103 s21, 8%; 5.7 3 103 s21, 9%), intermediate-
folding (9.0 3 102 to 1.5 3 101 s21, 24%), and slow-folding (5.9 3
1021 s21, 16%; 4.8 3 1021 s21, 43%) components in the protein
ensemble (Fig. 3 Inset). Although the relative populations and
the number of different rate constants vary slightly for kinetics
measured at different wavelengths, heterogeneous behavior is
always observed. On very long time scales, oxidation of the
reduced protein leads to some uncertainty in the extracted rate
constants (although the samples were carefully deoxygenated,
trace amounts of oxygen were always present). The transient
difference spectrum recorded 100 ms after electron injection is
characteristic of a mixture of five-coordinate, high-spin and
six-coordinate, low-spin ferrohemes, suggesting that the slower
folding populations are misligated. The difference spectra mea-
sured at 1 and 500 ms have been fit to a combination of the
[(FeII-folded) 2 (FeIII-unfolded)] and [(FeII-unfolded) 2 (FeIII-
unfolded)] molar difference spectra. The resulting folded and
unfolded populations (1 ms, 25% folded, 75% unfolded; 500 ms,
52% folded, 48% unfolded) are consistent with the measured
amplitude changes in the single wavelength kinetics.
FeII-Cyt c* Folding in the Presence of CO. To determine whether
misligated heme traps are responsible for the slow FeII–Cyt c9
folding, we examined ET-triggered folding of FeII–Cyt c9 in the
presence of CO. In the unfolded protein (3.32 M GuHCl, pH 7),
CO binding occurs with a millisecond time constant [1.0(4) 3 103
s21; 1 atm CO], whereas the folded protein binds CO much more
slowly [1.4(4) s21]. At lower denaturant concentration ([GuHCl]
5 2.1 M, pH 7) in the presence of CO, reduction of unfolded
FeIII–Cyt c9 is followed by two kinetics phases: a 1.4(6) 3 103 s21
step corresponding to CO binding, and 2.8(9) s21 component
due to FeII(CO)–Cyt c9 folding. The 1-ms transient difference
spectrum can be modeled by two absorbing species: the major
component is unfolded FeII(CO)–Cyt c9, and the minor fraction
is five-coordinate, folded FeII–Cyt c9. Subsequent changes in
absorbance are associated with the conversion of unfolded
FeII(CO)– to folded FeII(CO)–Cyt c9 (Fig. 4).
FeIII–Cyt c* Folding. Nonnative methionine-heme ligation is disfa-
vored in unfolded FeIII–Cyt c9 (37), and the axial heme coordi-
nation sites are occupied by water and His-117. The stopped-
flow triggered folding of FeIII–Cyt c9 is adequately described by
a single kinetics phase with a rate constant that decreases
exponentially with increasing denaturant concentration. The
folding rate constant [1.0(2) s21; [GuHCl] 5 0.95 M; DGf 5 216
kJ mol21] is comparable to that of FeII(CO)–Cyt c9 and of the
slower folding population of FeII–Cyt c9 ([GuHCl] 5 2.16 M;
DGf 5 210 kJ mol21). The extrapolated rate constant for folding
Fig. 3. Normalized folding kinetics (observed at 440 nm, black line) fit to 80
rate constants spanning logarithmically 105 to 1022 s21 (gray line) by using a
non-negative least-squares algorithm. (Upper) Residuals from the fit. (Inset)
The projected population of rate constants [7.0 3 103 s21 (8%); 5.7 3 103 (9%);
9.2 3 102 (1%); 2.2 3 102 (1%); 7.9 3 101 (11%); 1.9 3 101 (9%); 1.5 3 101 (2%);
5.9 3 1021 (16%); 4.8 3 1021 (43%)].
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FeIII–Cyt c9 in the absence of denaturant is 2.5 3 102 s21 [DGf°
5 233(3) kJ mol21).
Discussion
It is reasonable to expect that topologically homologous proteins
would fold at similar rates, yet cytochromes b562 and c9 display
quite disparate folding kinetics. Apparently, there are factors
beyond structural topology that must be considered to explain
the folding kinetics of these four-helix bundles. Three key
features of cytochromes b562 and c9 are likely to contribute to the
differences in folding kinetics: covalent attachment of the por-
phyrin to the polypeptide, nonnative heme–ligand traps, and
folding driving force.
The rapid dissociation of the heme from unfolded FeII–Cyt
b562 limits the time scale for observation of folding kinetics.
Because the porphyrin is covalently attached in Fe–Cyt c9, the
folding kinetics cover a far wider time range and are considerably
more complex. A fraction of the unfolded FeII–Cyt c9 ensemble
refolds rapidly, but several seconds are required for the entire
sample to fold. Proline isomerization is known to inhibit protein
folding (45) but is unlikely to be responsible for the slow Fe–Cyt
c9 kinetics. Although there are four proline residues in the Cyt
c9 sequence, the observed folding rates depend on denaturant
concentration and are substantially faster than typical proline
isomerizations (45). It is interesting to note that the fast-folding
fraction of FeII–Cyt c9 is roughly comparable to the yield of
folded FeII–Cyt b562. It is possible, then, that if heme dissociation
could be inhibited, FeII–Cyt b562 would display slower and more
complex folding kinetics.
The refolding of FeII–Cyt c9 can be described qualitatively by
a kinetic partitioning mechanism (46, 47). At the instant that
folding is initiated, a fraction of the denatured proteins will have
adopted conformations that can smoothly and rapidly fold to the
native structure. The fast-folding population of FeII–Cyt c9
would correspond to this group. Folding of the remaining
fraction is frustrated by transient trapping in local minima on the
folding energy landscape. Escape from these misfolded struc-
tures is an activated process that slows formation of the native
structure. The partition factor that determines the balance
between fast- and slow-folding populations depends on the
primary sequence as well as the refolding conditions (46–51).
Simulated folding kinetics of model three-helix-bundle proteins
(48, 49) point to a central role for the folding free-energy gap in
determining the partitioning between fast- and slow-track fold-
ing. The heterogeneous folding kinetics of FeII–Cyt c9 are
strikingly similar to the simulated folding kinetics of a small-gap
three-helix bundle (49).
Nonnative methionine ligands in unfolded FeII–Cyt c9 con-
tribute to the heterogeneity of the folding kinetics. In addition
to the fast-folding population, there are intermediate (’102 s21)
and slow-folding (,1 s21) components. Iron–sulfur bond disso-
ciation is not rate limiting because ferroheme–methionine ligand
exchange is faster than either folding phase (40). In the presence
of CO, the nonnative Met ligands are displaced from the
ferroheme, and folding is dominated by a slow phase with a time
constant of ’350 ms. Similarly, FeIII–Cyt c9 folding is not
complicated by heme–ligand binding, and a single 1-s phase
predominates. These observations suggest that, in the absence of
misligation, Cyt c9 requires 500 ms to 1 s to adopt a folded
structure. The presence of an intermediate (’102 s21) folding
phase in FeII–Cyt c9 implies that nonnative methionine ligation
can, in some instances, facilitate refolding. The protein has two
Met residues that can bind to the ferroheme when the protein
unfolds. It is possible that the intermediate phase arises from
protein populations with (H117N){PorN4FeII}(M15S) heme coor-
dination, and the slow phase corresponds to populations with
(H117N){PorN4FeII}(M25S) ligation (Fig. 4). Met-15 is in the distal
heme pocket in the folded protein, so an intermediate with
(H117N){PorN4FeII}(M15S) coordination might fold more readily
than a (H117N){PorN4FeII}(M25S) form.
The Fe–Cyt c9 folding rates are compared in Fig. 5 to those of
four structurally related proteins (11, 15, 19). The four-helix
bundles Im7 and Im9 have 60% sequence identity and nearly
identical three-dimensional structures, yet Im9 folds more than
10 times slower than Im7 (15). Curiously, Im9 displays the
hallmarks of two-state folding, whereas intermediates are im-
plicated in the faster Im7 folding process (15, 16). The folding of
ACBP has been interpreted in terms of a two-state model (12,
13), although subsequent quenched-flow hydrogen exchange
studies revealed that an intermediate is formed before the
rate-limiting step (14). Among helical-bundle structures, there is
a wide variation in measured folding rates as functions of 2DGf
Fig. 4. Schematic representation of heme coordination environment after
electron-transfer triggered folding of FeII–Cyt c9 in the presence and absence
of CO. The subscripts F and U refer to folded and unfolded polypeptides.
Fig. 5. Measured folding rates of helical proteins as functions of folding
driving force (DGf). Im7 (85 aa), pH 7, 10°C (n ) (15); Im9 (85 aa) (PDB 1IMQ,
upper right ribbon structure), pH 7, 10°C (h) (15); bovine ACBP (86 aa) (PDB
2ABD, upper left ribbon structure), pH 5.3, 5°C () (12); FeII–Cyt c9 (126 aa), pH
7, 22°C, slowest phase (E); FeIII–Cyt c9 (PDB 1A7V, lower right ribbon structure),
pH 7, 22°C (F); equine FeII–Cyt c (104 aa), pH 7, 22°C ({) (52); yeast FeII–Cyt c
(108 aa), pH 7, 22°C () (52).







(Fig. 5). It is clear that, even in the absence of misligation, Cyt
c9 is the slowest folding protein in this structural class. The
difference is even greater when account is taken of the fact that
the Im7, Im9, and ACBP folding kinetics were measured at
reduced temperatures. Cyt c9 is substantially larger than the
other helical bundles (Im7, 85 residues; Im9, 85 residues; ACBP,
86 residues; and Cyt c9, 126 residues), and its size may be in part
responsible for its slower folding. On a free-energy basis, the
Fe–Cyt c9 folding kinetics more closely resemble those of Cyt c
(52) than those of the nonheme helical-bundle proteins. Non-
native ligand binding clearly can perturb heme protein folding;
it is likely that noncovalent, nonnative heme–polypeptide con-
tacts represent additional sources of frustration.
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